Hillsdale Investment Management Inc. Otonomy, Inc. Transaction History

Hillsdale Investment Management Inc.

  • $1.13 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 09, 2021
SELL
$3.48 - $6.47 $689,847 - $1.28 Million
-198,232 Closed
0 $0
Q3 2020

Nov 13, 2020
BUY
$3.16 - $4.36 $626,413 - $864,291
198,232 New
198,232 $803,000

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Hillsdale Investment Management Inc. Portfolio

Follow Hillsdale Investment Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hillsdale Investment Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email